Autopsy report · NCT00366795

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

“Study was terminated due to safety reason.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 241 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Ascites; Liver Cirrhosis

Interventions

Satavaptan; placebo

Participants

241

Sites

21

Countries

Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Czechia, France, Germany, Malaysia and more

Trials that died the same way

• Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
  “The study terminated for safety reasons.” (94% match in meaning)
• Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)
  “The study was terminated due to administrative, non-safety related reasons.” (93% match in meaning)
• Randomized Controlled Study to Incentivize Doctors for Appropriate Use of Medical Care in NL
  “The study was terminated due to logistical reasons” (89% match in meaning)
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
  “Study was terminated due to administrative reasons” (88% match in meaning)
• An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
  “Study was prematurely terminated due to administrative and strategic reasons” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.